Abstract:Transcatheter tricuspid valve interventions (TTVI) are emerging as alternatives to surgery in high-risk patients with isolated or concomitant tricuspid regurgitation. The development of new minimally invasive solutions potentially more adapted to this largely undertreated population of patients, has fuelled the interest for the tricuspid valve. Growing evidence and new concepts have contributed to revise obsolete and misleading perceptions around the right side of the heart. New definitions, classifications, and a better understanding of the disease pathophysiology and phenotypes, as well as their associated patient journeys have profoundly and durably changed the landscape of tricuspid disease. A number of registries and a recent randomized controlled pivotal trial provide preliminary guidance for decision-making. TTVI seem to be very safe and effective in selected patients, although clinical benefits beyond improved quality of life remain to be demonstrated. Even if more efforts are needed, increased disease awareness is gaining momentum in the community and supports the establishment of dedicated expert valve centres. This review is summarizing the achievements in the field and provides perspectives for a less invasive management of a no-more-forgotten disease. Disease stage and therapeutic strategies for tricuspid regurgitation. Tricuspid regurgitation evolves from undetectable early forms to advanced stages characterized by escalating symptoms, right heart failure, and organ impairment. While medical therapy is utilized throughout the disease course, its effectiveness wanes with progression. Surgery can play a role in the earlier stages, while transcatheter therapies are available for patients at high risk and in the more advanced stages of disease. Significant overlap between treatment options underscores the urgent need for precise, evidence-based protocols. Overall, early intervention is crucial to prevent organ damage and avoid futility of late treatments (smileys becoming sad). CAVI, caval valve implantation; RHF, right heart failure; TR, tricuspid regurgitation; RA, right atrial; RV, right ventricular; TTV, transcatheter tricuspid valve.

Tricuspid Regurgitation: Disease State and Advances in Percutaneous Therapy

Insight into tricuspid transcatheter edge-to-edge repair: no longer the forgotten valve

New Therapeutic Advances in the Management of Tricuspid Valve Regurgitation

Tricuspid regurgitation: recent advances in understanding pathophysiology, severity grading and outcome.

Percutaneous repair of tricuspid regurgitation

The Current Landscape of Transcatheter Tricuspid Valve Intervention

Transcatheter interventions for severe tricuspid regurgitation: a literature review

Update on Transcatheter Tricuspid Valve Replacement Therapies

Transcatheter tricuspid valve interventions: Current devices and clinical evidence

Etiology, epidemiology, pathophysiology and management of tricuspid regurgitation: an overview.

Transcatheter tricuspid valve interventions: Current status and future perspectives

Percutaneous Tricuspid Valve Repair: The Triclip

Transcatheter Intervention for Management of Tricuspid Regurgitation Using TriClip

Contemporary evaluation and treatment of tricuspid regurgitation

Tricuspid insufficiency: from anatomy to function

Transcatheter Tricuspid Valve Interventions: A Triumph for Transcatheter Procedures?

Transcatheter treatment of the tricuspid valve: current status and perspectives

Tricuspid valve disease: diagnosis, prognosis and management of a rapidly evolving field

Contemporary diagnosis and management of severe tricuspid regurgitation

Real-World Patient Eligibility and Feasibility of Transcatheter Edge-to-Edge Repair or Replacement Interventions for Tricuspid Regurgitation

Multi-Modality Imaging in the Evaluation and Treatment of Tricuspid Regurgitation